Local cancer charity North West Cancer Research (NWCR) has recently chosen to invest over £600,000 in new, world-class cancer research projects based at the universities of Liverpool and Lancaster.

NWCR are one of the biggest cancer charities in the North West, formed by a recent merger between Clatterbridge Cancer Research and North West Cancer Research Fund. The charity aims to promote scientific understanding to fight cancer with world-class research.

Grants are awarded twice a year, in April and September. Submissions are reviewed by a panel of judges including leading professors, award-winning scientists and pioneering medical professionals.  The Chief Executive of NWCR, Anne Jackson said,  “The standard of grant submissions was exceptionally high this year and our panel of leading scientists and medical practitioners faced a serious challenge selecting the strongest applications.” .

NWCR prides itself on backing the very highest standard of research, ensuring best value for all donations. For every £1 donated, 85p goes directly to fund cancer research.

NWCR funds research across three main areas: Basic, Translational and Preventative at the Universities of Liverpool, Lancaster and Bangor. The five new projects supported focus on DNA damage, the characterisation of the endothelial cell surface molecules, biomarkers to detect pancreatic cancer earlier and studies into treatment of colorectal (bowel) cancer. Promoting research in these areas aims to improve our understanding of cancer, with view to translating this knowledge into viable new therapies that could potentially improve the treatment and management of cancer in the future.

List of projects:

Dr Nigel Jones1, Prof Alexander McLennan1, Dr Nikki Copeland2(Department of Biochemistry & Cell Biology, Institute of Integrative Biology, University of Liverpool1; Division of Biomedical & Life Sciences, Lancaster University2)

Title: Regulation of DNA replication by diadenosine nucleotides after DNA damage

£167,296 over 3 years

 

Dr Jason Parsons (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool)

Title: The cellular response to DNA damage: Ubiquitylation-dependent regulation of 8-oxoguanine DNA glycosylase (OGG1)

£114,670 over 3 years

Dr. Lu-Gang Yu1, Prof Jonathan Rhodes1 & Prof Robert Beynon2 (Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool1; Protein Function Group, Institute of Integrative Biology, University of Liverpool2)

Title: Characterization of the endothelial cell surface molecule(s) responsible for galectin-3-induced secretion of metastasis-promoting cytokine

£149,811 over 3 years

Dr Eithne Costello, Prof John Neoptolemos, Dr William Greenhalf, Prof Philip Johnson & Dr Trevor Cox (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool)

Title: Validation of serum biomarkers for pancreatic cancer detection

£118, 433 over 2 years

Dr. Neil Kitteringham1, Dr. Ian Copple1, Prof Daniel Palmer2 & Prof Kevin Park1

(Department of Molecular & Clinical Pharmacology1, Department of Molecular & Clinical Cancer Medicine2, Institute of Translational Medicine, University of Liverpool)

Title: Regulation of irinotecan anti-cancer pharmacology by Nrf2 – Implications for current use and potential for improved efficacy

£111,147 over 2 years